MoMa Therapeutics Stock

MOMA Therapeutics is committed to discovering the next generation of precision medicines by targeting molecular machines that underlie human disease. By focusing this platform on disease-causing targets, MOMA aims to develop high impact, precision medicines for patients with unmet medical needs. This company was founded in 2020 by Dorothee Kern, Eva Nogales, Johannes Walter, and Timur Yusufzai and is headquartered in Cambridge, MA.